Nunzia Pharmaceutical(OTC) NUNZ

Market Cap$43.50K

Since IPO (1995)-100%

5 Year-100%

1 Year+9,900%

1 Month+0%

$0.00

+0.00%

+0.00Today

Nunzia Pharmaceutical last closing stock price
Metric	Price	Date
Last close	USD 0.00	2026-06-05

Nunzia Pharmaceutical stock price return by period
Period	Price return	Price at period start	Period start date
1 week	+0%	USD 0.00	2026-05-04
1 month	+0%	USD 0.00	2026-05-04
3 month	+0%	USD 0.00	2026-01-30
Year to date	+0%	USD 0.00	2025-12-24
1 year	+9,900%	USD 0.00	2025-03-05
3 year	-99.8%	USD 0.05	2023-06-06
5 year	-99.99%	USD 1.73	2021-05-28
Since inception	-100%	USD 5,252,100.84	1995-02-27

Nunzia Pharmaceutical Financials at a Glance

Market Cap

$43.50K

Revenue (TTM)

$0.00

Net Income (TTM)

-$96.99M

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

-0.67 (Low)

Dividend

$0.00

Beta (Volatility)

-0.67 (Low)

Price

$0.00

Volume

Open

$0.00

Price

$0.00

Volume

Open

$0.00

Previous Close

$0.00

Daily Range

$0.00 - $0.00

52-Week Range

$0.00 - $0.00

Estimated Earnings Date

N/A

Dividend

$0.00

Beta (Volatility)

-0.67 (Low)

Price

$0.00

Volume

Open

$0.00

Previous Close

$0.00

Daily Range

$0.00 - $0.00

52-Week Range

$0.00 - $0.00

Estimated Earnings Date

N/A

NUNZ News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Nunzia Pharmaceutical

Nunzia Pharmaceutical Company is a pharmaceutical and nutraceutical firm focused on developing treatments for various disorders, including autism and ADHD. The company operates from Long Beach, California, and offers its products through wholesalers and its website.

Products and Services

Manufactures and distributes Nunzia, a nutraceutical for autism and ADHD
Offers products targeting PTSD and fragile X syndrome
Available through wholesalers and direct online sales

Growth Outlook

Market potential for nutraceuticals is expanding rapidly
Increased awareness of mental health disorders drives demand
Strategic partnerships may enhance distribution capabilities

Financial Highlights

Recent quarterly net income of -$245,403 reflects ongoing operational challenges
Trailing twelve months show a significant increase in general and administrative expenses
Cash and cash equivalents totaled $30,373 as of September 30, 2022

Nunzia Pharmaceutical Company is positioned in a growing market with a focus on addressing critical health issues. The company's unique product offerings and potential for strategic partnerships may provide avenues for future growth. However, recent financial data indicates challenges that need to be addressed for sustainable progress. Investors may find the company's focus on nutraceuticals and mental health treatment appealing, given the increasing demand in these sectors.

AI Generated • Aug 2, 2026

Industry

Personal Products

Sector

Consumer Staples

CEO

Charles A. Strongo, MBA

Website

www.nunziapharma.com

Headquarters

Long Beach, CA 90813, US

NUNZ Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

101661.22%

Return on Capital

-2387913.98%

Return on Assets

-1521431.14%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$43.50K

Shares Outstanding

434.51M

Volume

Avg. Volume

0.81

Financials (TTM)

Gross Profit

$0.00

Operating Income

-$96.97M

EBITDA

-$96.80M

Operating Cash Flow

-$277.92K

Capital Expenditure

$0.00

Free Cash Flow

-$277.92K

Cash & ST Invst.

$35.37K

Total Debt

$183.35K

Nunzia Pharmaceutical Performance Analysis

Nunzia Pharmaceutical annual revenue and year-over-year revenue growth by fiscal year
Fiscal year	Period end	Revenue	YoY growth
2021	2021-12-31	USD 0	N/A

Nunzia Pharmaceutical sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q4	2021-12-31	N/A
Q1	2022-03-31	N/A
Q2	2022-06-30	N/A
Q3	2022-09-30	N/A

Nunzia Pharmaceutical annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal year	Period end	Diluted EPS	YoY growth
2021	2021-12-31	USD -0.26	N/A

Nunzia Pharmaceutical sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q4	2021-12-31	-269900.0%
Q1	2022-03-31	84.0%
Q2	2022-06-30	99.9%
Q3	2022-09-30	-1196.1%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Currently no data to display.

Quarterly Performance

Name

Q3 2022YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

$43.50K

N/A

Market Cap/Employee

$10.88K

N/A

Employees

N/A

Net Income

-$245.40K

-610.8%

EBITDA

-$200.35K

-480.3%

Quarterly Fundamentals

Name

Q3 2022YOY CHG

Total Cash

$35.37K

+7223.6%

Total Debt

$183.35K

+697.2%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$183.35K

N/A

Return on Assets

-15214.31%

N/A

Return on Invested Capital

828.90%

N/A

Free Cash Flow

-$113.09K

-10987.1%

Operating Cash Flow

-$113.09K

-10987.1%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

WIBFFWest Island Brands Inc.

WIBFFWest Island Brands Inc.$0.00+0.00%

ARYXARYx Therapeutics, Inc.

ARYXARYx Therapeutics, Inc.$0.00+0.00%

VFRMVeritas Farms, Inc.

VFRMVeritas Farms, Inc.$0.00+0.00%

OWCPOWC Pharmaceutical Research Corp.

OWCPOWC Pharmaceutical Research Corp.$0.00+0.00%

ISOLFIsodiol International Inc.

ISOLFIsodiol International Inc.$0.00+0.00%

ONSSOnassis Holdings Corp.

ONSSOnassis Holdings Corp.$0.00+49.25%

QEBRVirtual Medical International, Inc.

QEBRVirtual Medical International, Inc.$0.00+0.00%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

PLTRPalantir Technologies

PLTRPalantir Technologies$162.66+0.29%

SPCXSpace Exploration Technologies

SPCXSpace Exploration Technologies$125.33+0.09%

NVDANvidia

NVDANvidia$211.94+0.03%

INTCIntel

INTCIntel$100.86+0.11%

AMIXAutonomix Medical

AMIXAutonomix Medical$19.50+4.34%

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares$8.07+0.03%

NOKNokia

NOKNokia$9.92+0.06%

Questions About NUNZ

What is the current price of Nunzia Pharmaceutical?

Nunzia Pharmaceutical is trading at $0.00 per share.

What is the 52-week range for Nunzia Pharmaceutical?

Over the past 52 weeks, Nunzia Pharmaceutical has traded between $0.00 and $0.00.

How much debt does Nunzia Pharmaceutical have?

As of the most recent reporting period, Nunzia Pharmaceutical reported total debt of $0.00.

How much cash does Nunzia Pharmaceutical have on hand?

Nunzia Pharmaceutical reported $131.00 in cash and cash equivalents in its most recent financial results.

What is Nunzia Pharmaceutical’s dividend yield?

Nunzia Pharmaceutical does not currently have a dividend yield.

Nunzia Pharmaceutical(OTC) NUNZ

Nunzia Pharmaceutical Financials at a Glance

NUNZ News

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Nunzia Pharmaceutical

NUNZ Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Nunzia Pharmaceutical Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About NUNZ

What is the current price of Nunzia Pharmaceutical?

What is the 52-week range for Nunzia Pharmaceutical?

How much debt does Nunzia Pharmaceutical have?

How much cash does Nunzia Pharmaceutical have on hand?

What is Nunzia Pharmaceutical’s dividend yield?

Premium Investing Services